Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies (TCP)

Etablissement Français du Sang

Status: Completed

Conditions: Multiple Myeloma; Lymphocytic Leukemia; Hodgkin Disease; Lymphoma

Treatments: Other: Platelet concentrate transfusion

Study type: Observational

Funder types: Other

Identifiers

NCT02885038

DR-2015-392 (Other Identifier)

CPP14/05

Details and patient eligibility

About

Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility, dose and source, may have an impact on transfusion responses and outcomes. Because of the relative scarcity of PCs the selection of a specific PC for issue to the patient remains a challenging process. Regulatory agencies do not fully address these characteristics in their recommendations for prophylactic transfusions.

The aim of the study was to analyse the effect of product-related factors in a real life setting, in order to determine which ones are the most relevant when selecting PCs for patients in prophylactic conditions. Two different endpoints are studied: the corrected count increment and the platelet transfusion time intervals.

Enrollment: 1,101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inpatients in the hematology department between January 2001 and December 2012
• Hematologic malignancy
• At least one platelet transfusion (with platelet count ≤ 25 G/L)
• Age 18 and over at time of first transfusion

Exclusion criteria

• More than one hematologic malignancy
• Non-malignant haematological disorder